JP2020007311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020007311A5 JP2020007311A5 JP2019135624A JP2019135624A JP2020007311A5 JP 2020007311 A5 JP2020007311 A5 JP 2020007311A5 JP 2019135624 A JP2019135624 A JP 2019135624A JP 2019135624 A JP2019135624 A JP 2019135624A JP 2020007311 A5 JP2020007311 A5 JP 2020007311A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- pharmaceutically acceptable
- compound according
- acceptable salt
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 40
- 239000012453 solvate Substances 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 6
- 208000032839 leukemia Diseases 0.000 claims 6
- -1 heterocyclo Chemical group 0.000 claims 5
- 230000003463 hyperproliferative effect Effects 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371504P | 2016-08-05 | 2016-08-05 | |
| US62/371,504 | 2016-08-05 | ||
| US201762454101P | 2017-02-03 | 2017-02-03 | |
| US62/454,101 | 2017-02-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506191A Division JP6651180B2 (ja) | 2016-08-05 | 2017-08-04 | Ｂｃｌ−２阻害剤としてのｎ−（フェニルスルホニル）ベンズアミドおよび関連化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020007311A JP2020007311A (ja) | 2020-01-16 |
| JP2020007311A5 true JP2020007311A5 (OSRAM) | 2020-09-03 |
| JP7205903B2 JP7205903B2 (ja) | 2023-01-17 |
Family
ID=59677319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506191A Active JP6651180B2 (ja) | 2016-08-05 | 2017-08-04 | Ｂｃｌ−２阻害剤としてのｎ−（フェニルスルホニル）ベンズアミドおよび関連化合物 |
| JP2019135624A Active JP7205903B2 (ja) | 2016-08-05 | 2019-07-23 | Ｂｃｌ－２阻害剤としてのｎ－（フェニルスルホニル）ベンズアミドおよび関連化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506191A Active JP6651180B2 (ja) | 2016-08-05 | 2017-08-04 | Ｂｃｌ−２阻害剤としてのｎ−（フェニルスルホニル）ベンズアミドおよび関連化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10829488B2 (OSRAM) |
| EP (3) | EP3569601B1 (OSRAM) |
| JP (2) | JP6651180B2 (OSRAM) |
| KR (2) | KR102429704B1 (OSRAM) |
| CN (2) | CN110483501B (OSRAM) |
| AU (2) | AU2017305508B2 (OSRAM) |
| CA (1) | CA3031419C (OSRAM) |
| CY (1) | CY1123859T1 (OSRAM) |
| DK (1) | DK3494115T3 (OSRAM) |
| ES (1) | ES2849959T3 (OSRAM) |
| HR (1) | HRP20202073T1 (OSRAM) |
| HU (1) | HUE053414T2 (OSRAM) |
| IL (2) | IL264059B (OSRAM) |
| LT (1) | LT3494115T (OSRAM) |
| MX (2) | MX381588B (OSRAM) |
| MY (1) | MY199409A (OSRAM) |
| PE (1) | PE20190711A1 (OSRAM) |
| PH (1) | PH12019500231A1 (OSRAM) |
| PT (1) | PT3494115T (OSRAM) |
| RS (1) | RS61821B1 (OSRAM) |
| RU (2) | RU2722560C1 (OSRAM) |
| SA (1) | SA519401020B1 (OSRAM) |
| SG (2) | SG11201900135YA (OSRAM) |
| SI (1) | SI3494115T1 (OSRAM) |
| SM (1) | SMT202100025T1 (OSRAM) |
| WO (1) | WO2018027097A1 (OSRAM) |
| ZA (2) | ZA201900240B (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11001582B2 (en) * | 2016-03-10 | 2021-05-11 | Assia Chemical Industries Ltd. | Solid state forms of Venetoclax and processes for preparation of Venetoclax |
| KR102429704B1 (ko) * | 2016-08-05 | 2022-08-04 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| WO2018127130A1 (en) | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| CN110546151B (zh) | 2017-04-18 | 2023-04-28 | 重庆复创医药研究有限公司 | 凋亡诱导剂 |
| FI3788042T3 (fi) | 2018-04-29 | 2025-04-07 | Beigene Switzerland Gmbh | Bcl-2-inhibiittoreita |
| US11554127B2 (en) * | 2018-07-31 | 2023-01-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| EP3672594B1 (en) * | 2018-07-31 | 2021-09-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| CA3095699A1 (en) * | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| EP3706741A4 (en) * | 2018-11-23 | 2022-03-30 | Ascentage Pharma (Suzhou) Co., Ltd. | PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| CN112168830B (zh) * | 2019-07-02 | 2022-01-25 | 苏州亚盛药业有限公司 | 一种含有mTOR抑制剂的药物组合及其应用 |
| WO2021018240A1 (en) * | 2019-07-31 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| TWI885019B (zh) | 2019-11-27 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
| EP3914251A4 (en) | 2019-12-03 | 2022-03-23 | Ascentage Pharma (Suzhou) Co., Ltd. | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS USED AS BCL-2 INHIBITORS |
| WO2021110136A1 (en) * | 2019-12-04 | 2021-06-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
| KR20220100992A (ko) | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
| TWI777438B (zh) * | 2020-03-06 | 2022-09-11 | 大陸商蘇州亞盛藥業有限公司 | N- (苯基磺醯基) 苯甲醯胺類化合物的結晶形式 |
| US20230128137A1 (en) * | 2020-03-12 | 2023-04-27 | Medshine Discovery Inc. | Benzo five-membered cyclic compound |
| TW202200574A (zh) | 2020-04-15 | 2022-01-01 | 英屬開曼群島商百濟神州有限公司 | Bcl-2抑制劑 |
| WO2021227763A1 (en) * | 2020-05-14 | 2021-11-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Hplc analysis method for n- (phenylsulfonyl) benzamide compound |
| US20230159524A1 (en) * | 2020-07-01 | 2023-05-25 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof |
| CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
| CN115697967B (zh) * | 2020-07-10 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用 |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| US20230398110A1 (en) * | 2020-08-21 | 2023-12-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| CN114073707A (zh) * | 2020-08-21 | 2022-02-22 | 苏州亚盛药业有限公司 | 治疗系统性红斑狼疮的组合物和方法 |
| WO2022111558A1 (en) * | 2020-11-25 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Solid dispersion, pharmaceutical preparations, preparation method, and application thereof |
| US20240316069A1 (en) * | 2020-12-28 | 2024-09-26 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods of treating multiple sclerosis |
| US20240166644A1 (en) * | 2021-02-01 | 2024-05-23 | Ascentage Pharma (Suzhou) Co., Ltd. | Sulfonyl benzamide derivatives as bcl-2 inhibitors |
| WO2022216942A1 (en) | 2021-04-07 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| CN117957018A (zh) | 2021-08-02 | 2024-04-30 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| CA3238433A1 (en) * | 2021-12-06 | 2023-06-15 | Xingguo LIU | Anti-apoptotic protein bcl-2 inhibitor, pharmaceutical composition and uses thereof |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
| EP4421075A1 (en) * | 2023-02-27 | 2024-08-28 | KRKA, d.d., Novo mesto | Process for the preparation of venetoclax and intermediates used therein |
| CN121175043A (zh) | 2023-03-03 | 2025-12-19 | 伊昂克图拉股份有限公司 | 用于治疗血液恶性肿瘤的罗吉诺利西布与bcl-2抑制剂的组合 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021343A (en) | 1912-01-17 | 1912-03-26 | M A N Mfg Company | Locking-clamp. |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| JP5277168B2 (ja) | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| AU2007329458A1 (en) | 2006-12-04 | 2008-06-12 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| EP2376480B1 (en) | 2008-12-05 | 2016-06-01 | AbbVie Inc. | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| CN104945311A (zh) * | 2009-01-19 | 2015-09-30 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| MX2011008488A (es) | 2009-02-11 | 2011-10-24 | Abbott Lab | Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2. |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| BR122019016429B1 (pt) | 2009-05-26 | 2020-03-24 | Abbvie Ireland Unlimited Company | Compostos inibidores da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo ditos compostos |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| ES2699205T3 (es) * | 2010-10-29 | 2019-02-07 | Abbvie Inc | Dispersiones sólidas que contienen un agente que induce la apoptosis |
| NZ708508A (en) | 2010-11-23 | 2016-06-24 | Abbvie Bahamas Ltd | Methods of treatment using selective bcl-2 inhibitors |
| AU2011332043C1 (en) | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| JP6960912B2 (ja) | 2015-12-30 | 2021-11-05 | デックスコム・インコーポレーテッド | 感度プロファイルに基づく留置センサの工場校正または不完全校正のためのシステム及び方法 |
| KR102429704B1 (ko) * | 2016-08-05 | 2022-08-04 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
-
2017
- 2017-08-04 KR KR1020217026744A patent/KR102429704B1/ko active Active
- 2017-08-04 EP EP19184604.7A patent/EP3569601B1/en active Active
- 2017-08-04 KR KR1020197002744A patent/KR102376764B1/ko active Active
- 2017-08-04 RU RU2019105721A patent/RU2722560C1/ru active
- 2017-08-04 SG SG11201900135YA patent/SG11201900135YA/en unknown
- 2017-08-04 PT PT177548898T patent/PT3494115T/pt unknown
- 2017-08-04 SI SI201730535T patent/SI3494115T1/sl unknown
- 2017-08-04 WO PCT/US2017/045428 patent/WO2018027097A1/en not_active Ceased
- 2017-08-04 HU HUE17754889A patent/HUE053414T2/hu unknown
- 2017-08-04 HR HRP20202073TT patent/HRP20202073T1/hr unknown
- 2017-08-04 SM SM20210025T patent/SMT202100025T1/it unknown
- 2017-08-04 SG SG10201913643YA patent/SG10201913643YA/en unknown
- 2017-08-04 RU RU2020114660A patent/RU2744358C2/ru active
- 2017-08-04 MX MX2019001391A patent/MX381588B/es unknown
- 2017-08-04 CA CA3031419A patent/CA3031419C/en active Active
- 2017-08-04 MY MYPI2019000239A patent/MY199409A/en unknown
- 2017-08-04 CN CN201910626474.XA patent/CN110483501B/zh active Active
- 2017-08-04 CN CN201780035965.6A patent/CN109311871B/zh active Active
- 2017-08-04 EP EP22179906.7A patent/EP4129999A1/en active Pending
- 2017-08-04 RS RS20201599A patent/RS61821B1/sr unknown
- 2017-08-04 ES ES17754889T patent/ES2849959T3/es active Active
- 2017-08-04 LT LTEP17754889.8T patent/LT3494115T/lt unknown
- 2017-08-04 EP EP17754889.8A patent/EP3494115B1/en active Active
- 2017-08-04 DK DK17754889.8T patent/DK3494115T3/da active
- 2017-08-04 US US16/317,056 patent/US10829488B2/en active Active
- 2017-08-04 PE PE2019000335A patent/PE20190711A1/es unknown
- 2017-08-04 JP JP2019506191A patent/JP6651180B2/ja active Active
- 2017-08-04 AU AU2017305508A patent/AU2017305508B2/en active Active
-
2018
- 2018-08-01 US US16/051,816 patent/US10221174B2/en active Active
-
2019
- 2019-01-02 IL IL264059A patent/IL264059B/en active IP Right Grant
- 2019-01-14 ZA ZA2019/00240A patent/ZA201900240B/en unknown
- 2019-01-31 MX MX2020013014A patent/MX2020013014A/es unknown
- 2019-01-31 PH PH12019500231A patent/PH12019500231A1/en unknown
- 2019-02-04 SA SA519401020A patent/SA519401020B1/ar unknown
- 2019-07-23 JP JP2019135624A patent/JP7205903B2/ja active Active
- 2019-12-19 ZA ZA2019/08466A patent/ZA201908466B/en unknown
-
2020
- 2020-09-17 US US17/023,426 patent/US11718613B2/en active Active
-
2021
- 2021-01-15 CY CY20211100032T patent/CY1123859T1/el unknown
- 2021-04-06 IL IL282099A patent/IL282099B/en unknown
- 2021-04-06 AU AU2021202113A patent/AU2021202113B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020007311A5 (OSRAM) | ||
| CN115244058A (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2019511528A5 (OSRAM) | ||
| JP2018516917A5 (OSRAM) | ||
| JPWO2021168193A5 (OSRAM) | ||
| JP2019535746A5 (OSRAM) | ||
| JP2019510798A5 (OSRAM) | ||
| JP2020532532A5 (OSRAM) | ||
| JP2014193925A5 (OSRAM) | ||
| JP2018526413A5 (OSRAM) | ||
| JP2003522163A5 (OSRAM) | ||
| JP2007529421A5 (OSRAM) | ||
| JP2019511564A5 (OSRAM) | ||
| JP2019507114A5 (OSRAM) | ||
| JPWO2021060453A5 (OSRAM) | ||
| JP2011509302A5 (OSRAM) | ||
| JP2020531414A5 (OSRAM) | ||
| JPWO2020023560A5 (OSRAM) | ||
| JP2020514344A5 (OSRAM) | ||
| RU2011134283A (ru) | Имидазотиазольные производные, имеющие пролиновую циклическую структуру | |
| JPWO2020163823A5 (OSRAM) | ||
| JP2010519221A5 (OSRAM) | ||
| RU2426539C2 (ru) | Способы лечения устойчивого к лекарственным средствам рака | |
| JP2018532786A5 (OSRAM) |